• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性硬化症患者的临界平均肺动脉压:跨肺压差可预测发生肺动脉高压的风险。

Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.

作者信息

Valerio Christopher J, Schreiber Benjamin E, Handler Clive E, Denton Christopher P, Coghlan John G

机构信息

National Pulmonary Hypertension Unit,, Royal Free Hospital, London, UK.

出版信息

Arthritis Rheum. 2013 Apr;65(4):1074-84. doi: 10.1002/art.37838.

DOI:10.1002/art.37838
PMID:23280155
Abstract

OBJECTIVE

To determine whether patients with systemic sclerosis (SSc) and borderline mean pulmonary artery pressure (PAP) at cardiac catheterization are more likely to develop pulmonary hypertension (PH) than those in whom pulmonary pressure is normal.

METHODS

Patients with SSc in whom PH and significant interstitial lung disease had been excluded at baseline were enrolled in our prospective cohort. Analysis of followup data identified patients who met prespecified criteria prompting repeat catheterization to reassess for possible PH. Using Kaplan-Meier, receiver operating characteristic, and Cox regression methods, we studied the development of PH and death.

RESULTS

Of 228 patients in this study, 86 had borderline mean PAP (21-24 mm Hg) at baseline. Following prespecified criteria, 76 patients underwent repeat catheterization, and 29 of these developed PH. Two cases were related to disease of the left side of the heart. The average mean PAP increased from baseline (20.2 mm Hg) to followup (24.3 mm Hg) (P<0.05 by Student's t-test). Patients with borderline mean PAP were more likely to develop PH than patients with mean PAP≤20 mm Hg (P<0.001 by log rank test, hazard ratio [HR] 3.7). A transpulmonary gradient (TPG)≥11 mm Hg at baseline also predicted PH (P<0.001 by log rank test, HR 7.9). Incident development of pulmonary arterial hypertension (PAH) was not benign, with a mortality of 18% within 3 years.

CONCLUSION

Our findings indicate that borderline mean PAP and an elevated TPG in patients with SSc predict progression to PH. These patients should be monitored closely for the development of PH. Our findings indicate that catheterization data are useful in patients considered at risk of PAH.

摘要

目的

确定在心脏导管检查时患有系统性硬化症(SSc)且平均肺动脉压(PAP)处于临界值的患者与肺动脉压力正常的患者相比,是否更易发生肺动脉高压(PH)。

方法

将基线时已排除PH和严重间质性肺病的SSc患者纳入我们的前瞻性队列研究。对随访数据进行分析,确定符合预先设定标准的患者,促使其再次进行导管检查以重新评估是否可能患有PH。我们使用Kaplan-Meier法、受试者工作特征曲线法和Cox回归方法研究PH的发生情况和死亡情况。

结果

本研究的228例患者中,86例在基线时平均PAP处于临界值(21 - 24 mmHg)。按照预先设定的标准,76例患者接受了再次导管检查,其中29例发生了PH。2例与心脏左侧疾病有关。平均PAP平均值从基线时的(20.2 mmHg)升至随访时的(24.3 mmHg)(经Student t检验,P<0.05)。平均PAP处于临界值的患者比平均PAP≤20 mmHg的患者更易发生PH(经对数秩检验,P<0.001,风险比[HR]为3.7)。基线时跨肺压差(TPG)≥11 mmHg也可预测PH(经对数秩检验,P<0.001,HR为7.9)。肺动脉高压(PAH)的新发情况并非良性,3年内死亡率为18%。

结论

我们的研究结果表明,SSc患者平均PAP处于临界值和TPG升高可预测进展为PH。这些患者应密切监测PH的发生情况。我们的研究结果表明,导管检查数据对被认为有PAH风险的患者有用。

相似文献

1
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.系统性硬化症患者的临界平均肺动脉压:跨肺压差可预测发生肺动脉高压的风险。
Arthritis Rheum. 2013 Apr;65(4):1074-84. doi: 10.1002/art.37838.
2
Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.合并肺动脉高压及楔压升高的系统性硬化症患者的临床特征与生存情况:来自PHAROS队列的观察结果
Respirology. 2017 Oct;22(7):1386-1392. doi: 10.1111/resp.13067. Epub 2017 May 12.
3
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.高N末端脑钠肽前体水平和低一氧化碳弥散能力作为系统性硬化症患者毛细血管前肺动脉高压发生的独立预测因素。
Arthritis Rheum. 2008 Jan;58(1):284-91. doi: 10.1002/art.23187.
4
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.系统性硬皮病相关性肺动脉高压和间质性肺病患者的移植后生存率提高。
Arthritis Rheumatol. 2014 Jul;66(7):1900-8. doi: 10.1002/art.38623.
5
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.肺动脉高压治疗对于系统性硬化症和临界肺动脉压患者可能是安全有效的。
Arthritis Rheum. 2012 Apr;64(4):1257-62. doi: 10.1002/art.33460. Epub 2011 Nov 11.
6
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.与间质性肺疾病相关的系统性硬化症相关性肺动脉高压:肺动脉高压治疗的影响
Arthritis Rheum. 2011 Aug;63(8):2456-64. doi: 10.1002/art.30423.
7
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.在法国一项全国性多中心纵向研究中,系统性硬化症相关肺动脉高压的三年发病率。
Arthritis Rheum. 2009 Jun;60(6):1831-9. doi: 10.1002/art.24525.
8
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.N 端脑钠肽前体(N-TproBNP)在硬皮病相关肺动脉高压中的作用
Eur Heart J. 2006 Jun;27(12):1485-94. doi: 10.1093/eurheartj/ehi891. Epub 2006 Apr 27.
9
Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis.超声心动图在系统性硬化症患者肺动脉压过度升高中的应用价值。
Kardiol Pol. 2011;69(1):9-15.
10
Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.泰国系统性硬化症合并肺动脉高压患者的死亡率预后因素和 2 年生存率分析。
Int J Rheum Dis. 2011 Aug;14(3):282-9. doi: 10.1111/j.1756-185X.2011.01625.x. Epub 2011 Jun 30.

引用本文的文献

1
A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS (HAPPINESS study): protocol and baseline data for an observational study.日本东部系统性硬化症相关肺动脉高压队列研究(HAPPINESS研究):一项观察性研究的方案和基线数据
BMC Rheumatol. 2025 Feb 26;9(1):25. doi: 10.1186/s41927-025-00474-2.
2
Shifting Paradigms in the Management of Pulmonary Hypertension.肺动脉高压管理中的范式转变
Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. eCollection 2024.
3
The latest definition and classification of pulmonary hypertension.
肺动脉高压的最新定义和分类。
Int J Cardiol Congenit Heart Dis. 2024 Jul 31;17:100534. doi: 10.1016/j.ijcchd.2024.100534. eCollection 2024 Sep.
4
Exercise pulmonary hypertension in patients with systemic sclerosis based on updated guidelines.根据更新的指南,对系统性硬皮病患者进行运动性肺动脉高压检查。
Sci Rep. 2024 Jun 11;14(1):13358. doi: 10.1038/s41598-024-63823-0.
5
Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.硬皮病肺血管早期病变(SEPVADIS)患者应用西地那非与安慰剂的随机对照试验研究方案
BMC Pulm Med. 2024 Apr 30;24(1):211. doi: 10.1186/s12890-024-02892-3.
6
Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.内皮素受体拮抗剂致肝损伤:基于上市后药物监测数据的真实世界研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231223606. doi: 10.1177/17534666231223606.
7
Significance of Hypocapnia in the Risk Assessment of Patients with Pulmonary Hypertension.低碳酸血症在肺动脉高压患者风险评估中的意义
J Clin Med. 2023 Sep 30;12(19):6307. doi: 10.3390/jcm12196307.
8
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study.根据 2022 年 ESC/ERS 指南预测轻度肺动脉高压的结局:EVIDENCE-PAH UK 研究。
Eur Heart J. 2023 Nov 21;44(44):4678-4691. doi: 10.1093/eurheartj/ehad532.
9
Pulmonary Hypertension: A Contemporary Review.肺动脉高压:当代综述。
Am J Respir Crit Care Med. 2023 Sep 1;208(5):528-548. doi: 10.1164/rccm.202302-0327SO.
10
Reappraisal of the Transthoracic Echocardiographic Algorithm in Predicting Pulmonary Hypertension Redefined by Updated Pulmonary Artery Mean Pressure Threshold.经更新的肺动脉平均压阈值定义的肺动脉高压重新评估的经胸超声心动图算法。
Anatol J Cardiol. 2023 Jun;27(6):348-359. doi: 10.14744/AnatolJCardiol.2023.2435.